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Abstract The ability to genetically manipulate
mice has led to rapid progress in our understand-
ing of the roles of different gene products in
human disease. Transgenic mice have often been
created in the FVB/NJ (FVB) strain due to its
high fecundity, while gene-targeted mice have
been developed in the 129/SvJ-C57Bl/6J strains
due to the capacity of 129/SvJ embryonic stem
cells to facilitate germline transmission. Gene-
targeted mice are commonly backcrossed into the
C57Bl/6J (B6) background for comparison with
existing data. Genetic modiﬁers have been shown
to modulate mammary tumor latency in mouse
models of breast cancer and it is commonly
known that the FVB strain is susceptible to
mammary tumors while the B6 strain is more
resistant. Since gene-targeted mice in the B6
background are frequently bred into the polyo-
mavirus middle T (PyMT) mouse model of breast
cancer in the FVB strain, we have sought to
understand the impact of the different genetic
backgrounds on the resulting phenotype. We bred
mice deﬁcient in the inducible nitric oxide
synthase (iNOS) until they were congenic in the
PyMT model in the FVB and B6 strains. Our
results reveal that the large difference in mean
tumor latencies in the two backgrounds of 53 and
92 days respectively affect the ability to discern
smaller differences in latency due to the Nos2
genetic mutation. Furthermore, the longer latency
in the B6 strain enables a more detailed analysis
of tumor formation indicating that individual
tumor development is not stoichastic, but is
initiated in the #1 glands and proceeds in early
and late phases. NO production affects tumors
that develop early suggesting an association of
iNOS-induced NO with a more aggressive tumor
phenotype, consistent with human clinical data
positively correlating iNOS expression with
breast cancer progression. An examination of
lung metastases, which are signiﬁcantly reduced
in PyMT/iNOS
–/– mice compared with PyMT/
iNOS
+/+ mice only in the B6 background, is
concordant with these ﬁndings. Our data suggest
that PyMT in the B6 background provides a
useful model for the study of inﬂammation-
induced breast cancer.
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Introduction
Transgenic mouse models that develop spontane-
ous mammary adenocarcinomas have proven
valuable in revealing molecular mechanisms
underlying tumorigenesis and metastasis (Cardiff
2003; Fargiano et al. 2003). Models target speciﬁc
pathways depending on the transgene being
expressed under the control of the mouse mam-
mary tumor virus long terminal repeat (MMTV-
LTR) or whey acid protein (WAP) mammary
gland promoters and thereby replicate genetic
defects in subsets of human tumors (Cardiff and
Wellings 1999; Rosner et al. 2002). Molecules
from pathways known to be important in the
pathogenesis of human breast cancer such as the
Wnt, Ras and ErbB2/Neu pathways have been
utilized, however few spontaneous mammary
tumor model systems develop metastasis, a cru-
cial aspect of cancer progression.
As demonstrated by gene expression analysis
(Ma et al. 2003), the polyomavirus middle T
(PyMT) model in the FVB/N (FVB) background
activates the same signaling pathways as erbB2,
an oncogene ampliﬁed or overexpressed in
approximately 30% of human breast cancers.
The model has been particularly useful for
genetic studies due to its short tumor latency
and high incidence of pulmonary metastasis (Guy
et al. 1992). These features have enabled global
expression proﬁling of PyMT tumors from differ-
ent genetic backgrounds to identify signatures of
tumor virulence (Qiu et al. 2004) that are consis-
tent with a gene set predictive of metastasis in
human tumors (Ramaswamy et al. 2003). Hence,
the model has been used effectively to dissect
early and late stages of mammary tumor devel-
opment (Guy et al. 1994; Lin et al. 2001; Webster
et al. 1998; Williams et al. 2004). In women with
breast cancers involving this pathway, the course
of the disease varies widely. One powerful means
to understand that variability is to identify useful
animal models. The PyMT breast cancer model
can be used in genetic crossing experiments to
identify loci having modiﬁer effects on either
tumorigenesis or metastasis (Le Voyer et al.
2000). An understanding of the genetic polymor-
phisms underlying these effects is important in
the study of human cancer as genetic variability
affects host-tumor interactions in numerous ways
and is an important factor in the response to
therapy.
Widely varied tumor responses to polyoma
virus infection among different inbred strains of
mice have been well documented (Freund et al.
1992; Gross 1983). Much of this difference can be
attributed to the major histocompatibility com-
plex (MHC) which results in immunologically
mediated resistance associated with an H-2
b
haplotype such as in C57Bl strains (Law et al.
1967; Ting and Law 1965). Other inbred strains,
notably those with the H-2
d and H-2
k haplotypes
have moderate and weak tumor resistance
respectively (Freund et al. 1992). The FVB strain
has an H-2
q haplotype, which may be an addi-
tional MHC locus that confers susceptibility to
polyoma virus induced tumorigenesis. Alterna-
tively, non-MHC genes can also result in a
dominant pattern of tumor susceptibility as in
the case of the C3H/BiDa strain (Freund et al.
1992).
Strain variations are also relevant to the study
of genetic mutations in mouse models of disease.
An analysis of targeted disruptions on mammary
tumorigenesis in the PyMT model requires breed-
ing of knockout models usually developed in the
129/SvJ-C57Bl/6J background into the FVB back-
ground. It is commonly recognized that the FVB
strain is susceptible while the C57Bl/6J (B6)
strain is more resistant to PyMT mammary
tumorigenesis and F1 crosses of these strains
increase tumor latency by approximately 6 days
(Lifsted et al. 1998). However, it is not clear what
effects continued backcrossing has on the analysis
of targeted mutations in the PyMT model.
Previously we reported that inducible nitric
oxide synthase (iNOS) deﬁciency in the PyMT
model in the B6 background resulted in an
increase in tumor latency that was not observed
in the FVB background (Ellies et al. 2003). Since
the issue of strain background is an important one
for analysis of mouse models we have made iNOS
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123knockout mice congenic in the FVB and B6
backgrounds and carried out a comparison of
tumorigenesis and metastasis in both strains.
Materials and methods
Animals
PyMT (FVB/N-Tg(MMTV-PyVT)634Mul/J) mice
(Guy et al. 1992) were obtained from W. Muller
(McMaster University, Ontario, Canada). We
acquired PyMT mice that had been backcrossed
5 generations into the B6 background from A.
Varki (UCSD, La Jolla, CA). Control (C57Bl/6J)
and iNOS deﬁcient mice (B6.129P2-Nos2
tm1Lau/J;
Laubach et al. 1995) were purchased from The
Jackson Laboratory, Bar Harbor, ME. The PyMT
B6micewerefurtherbackcrosseduntilcongenicin
the B6 background and then bred with iNOS
–/–
mice. iNOS
–/– mice were bred into the FVB
background until congenic (>10 generations) and
then crossed with PyMT FVB mice. Female mice
heterozygous for the PyMT transgene and homo-
zygous for the wild type or mutated iNOS gene
were used in these studies. For clarity and brevity,
we have designated FVB/N-Tg(MMTV-PyVT)
634Mul/JxB6.129P2-Nos2
tm1Lau/J
+/+ mice PyMT/
iNOS
+/+ and FVB/N-Tg(MMTV-PyVT)634Mul/
JxB6.129P2-Nos2
tm1Lau/J
–/– mice PyMT/iNOS
–/–.
FVB mice were palpated twice weekly from
4 weeks of age and B6 mice once weekly from
8 weeks of age to monitor mammary tumor
development. Tumors were measured in 2 dimen-
sions using calipers and tumor volume estimated
using the standard calculation for a sphere 4/3 ·
3.14 · a · b
2whereaisthesmallerdiameter andb
is the larger diameter. After euthanizing the mice,
mammary tumors were dissected and weighed and
the total tumor burden calculated (tumor weight/
body weight). All studies followed the NIH
guidelines for the care and treatment of experi-
mental laboratory rodents.
Mammary gland whole mounts
Pairs of inguinal mammary glands were ﬁxed in
formalin or Carnoy’s ﬁxative, dehydrated through
a graded series of ethanol solutions and defatted
in xylene. Following rehydration, the mammary
epithelium was stained with carmine stain (Sigma
Chemical, St Louis, MO) for 30 min. After
removing excess stain by washing in water,
samples were dehydrated and stored in methyl
salicylate (Sigma Chemical, St Louis, MO).
Tumor microvascular density
Cryosections of OCT embedded tumor samples
were cut at 7 lm and stained with anti-CD31
clone 13.3 (1:200, BD Pharmingen, San Diego,
CA) as previously described (Ellies et al. 2003).
Five random ﬁelds per tumor were captured on
the Spot RT digital camera system (Diagnostic
Instruments, Sterling Heights, MI) at 200· mag-
niﬁcation and analyzed using the public domain
NIH Image program (http://rsb.info.nih.gov/nih-
image/). Microvessel areas were normalized to
1m m
2 of epithelium.
Lung metastases
Parafﬁn embedded lungs were serial sectioned
and stained with hematoxylin and eosin. Both
the numbers and areas of lung metastases were
measured by light microscopy using images and
software from the Spot RT digital camera
system. Lung area per section was measured
using a dissecting scope and metastatic tumor
burden calculated (mm
2 of lung metastases/cm
2
of lung tissue) for each animal using data from 3
sections at least 100 lm apart. At least 13
PyMT/iNOS
+/+ or PyMT/iNOS
–/– mice were
used in this analysis.
Statistical analysis
The percentage of mice tumor free in each
group was analyzed using a Kaplan-Meier sur-
vival analysis, and the log-rank statistic was
used for comparison of the curves between
groups. The t-test was used for comparison of 2
groups and the analysis of variance (ANOVA)
followed by the Bonferroni post-test was
applied to multiple comparisons. The Mann–
Whitney U test was used to compare metastastic
burden in the PyMT/iNOS
+/+ and PyMT/
iNOS
–/– groups.
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PyMT tumorigenesis is delayed in the C57Bl/6
strain
The PyMT model was originally developed in the
FVB strain due to its high fecundity. Tumor
growth occurs rapidly and metastatic tumors form
in the lungs (Guy et al. 1992). To compare
tumorigenesis in the FVB strain with that in the
C57Bl/6 strain onto which many genetically
modiﬁed strains are bred, we made PyMT mice
congenic in the B6 background. Examination of
tumor latency showed a dramatic difference with
a mean latency of 53 days for PyMT tumor
development in FVB mice and 92 days in B6
mice, a delay of approximately 6 weeks (Fig. 1A).
Whole mounts of mammary glands from the two
strains also showed that even at weaning, hyper-
plasias were more advanced in FVB than B6
PyMT mice (Fig. 1B).
Effects of iNOS deﬁciency are more apparent
in the C57Bl/6 background
To determine how this difference in tumor
latency may affect the phenotype observed fol-
lowing crossbreeding with genetically altered
mice, we bred in iNOS
–/– mice congenic in the
two backgrounds. As previously reported, we
observed a 3–4 week delay in palpable tumors in
B6 PyMT mice lacking iNOS activity (Ellies et al.
2003). However, this difference was difﬁcult to
discern in the FVB background due to the rapid
tumor onset (Fig. 2A). Mammary gland whole
mounts reﬂected the latency data with a clear
difference in tumor growth with iNOS deﬁciency
being observed in the #4 glands of B6 PyMT mice
(Fig. 2A).
PyMT tumor growth kinetics vary in FVB/N
and C57Bl/6 strains
The pattern of tumor growth differed between
strains and may in part account for the greater
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Fig. 1 PyMT tumorigenesis in the FVB and B6 strains.
(A) The day at which the ﬁrst mammary tumor was
detected by palpation in each mouse was recorded and a
Kaplan-Meier survival plot generated. Log rank analysis
indicated a highly signiﬁcant difference, P < 0.001 between
the curves. FVB mice N = 44, B6 mice N = 46. (B)
Whole mounts of mammary glands from 3 week old
PyMT/iNOS
+/+ mice of the FVB (left panel) and B6 (right
panel) strains
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Fig. 2 Effects of iNOS deﬁciency on mammary tumor
development. (A) Whole mounts of PyMT/iNOS
+/+ and
PyMT/iNOS
–/– #4 mammary glands from 11 week FVB
mice or 20 week B6 mice. LN = lymph node. (B) Kaplan
Meier plots of the tumor latency of PyMT/iNOS
+/+ annd
PyMT/iNOS
–/– mice of the 2 strains. Data were analyzed
by the log rank test. PyMT/iNOS
+/+ FVB N = 44,
PyMT/iNOS
–/– FVB N = 57, PyMT/iNOS
+/+ B6
N = 46, PyMT/iNOS
–/– B6 N =2 6
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123disparity in tumor development observed in the
absence of iNOS in PyMT B6 mice. Once the
mean tumor volume reached 1 cm
3, tumor
growth proceeded exponentially in the PyMT
FVB mice leading to sacriﬁce within 3 weeks
(Fig. 3A). To achieve the same ﬁnal tumor
volume, the PyMT B6 mice required approxi-
mately 7 weeks and growth followed a more
linear pattern, suggesting more variable rates of
growth of individual tumors. Indeed, when we
analyzed the tumor latency of all tumors, we
were able to deﬁne two distinct phases of tumor
growth in the B6 strain: early, from 12–
17 weeks and late, from 19–23 weeks (Fig. 3B).
The major effect of iNOS deﬁciency appears to
be a delay in the early phase of tumor
development.
Deﬁciency in iNOS-modulated tumor growth
is site speciﬁc
In concordance with increased tumor latency and
decreased tumor growth (Ellies et al. 2003) tumor
burden was signiﬁcantly lower in PyMT/iNOS
–/–
mice (Fig. 4A). An examination of tumor burden
in individual mammary glands revealed a reduc-
tion in all PyMT/iNOS
–/– glands compared to
controls, although the numbers were only signif-
icant in the #3 and #4 mammary glands (Fig. 4A).
It is interesting to note that these are the glands
with the largest fat pads and may indicate a role
for the stroma in the iNOS effect. To assess a role
for tumor vascularization in this effect we exam-
ined tumor microvascular density (MVD) in
#1and #2–5 tumors of both genotypes. Although
there was a slight reduction in the mean MVD in
#1 versus #2–5 tumors in the PyMT/iNOS
+/+ and
PyMT/iNOS
–/– genotypes, it was not statistically
signiﬁcant, suggesting this is not the mechanism
for the difference observed in tumor growth at
different locations (Table 1).
This site-speciﬁc effect prompted us to exam-
ine tumor latency in individual glands. We had
observed during palpations that the #1 mammary
gland was usually the ﬁrst to develop tumors,
however we were surprised to ﬁnd a clear
difference between the latency of the #1 tumors
compared with all other tumors (Fig. 5). This
difference was more noticeable in the absence of
iNOS. The greater difference in mean latency in
the #4 glands compared with the #1 glands was
consistent with the tumor burden results being
more signiﬁcant in the #4 glands.
iNOS effects on tumor metastasis
The PyMT model has been useful for the study of
tumor metastasis due to the high penetrance of
this clinically important characteristic of tumor
progression. However, we found that in the FVB
strain, tumors were so aggressive that no signif-
icant difference could be observed in the meta-
static burden occurring in PyMT/iNOS
+/+ and
PyMT/iNOS
–/– mice Fig 6. Although the inci-
dence of tumor metastasis was less in the B6
strain, a statistically signiﬁcant difference
between the genotypes was found. We have
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Fig. 3 Mammary tumor growth kinetics. (A) Mean tumor
volume per mouse. FVB N = 32, B6 N = 44. Data
are means ± SEM. (B) Tumor latency for individual B6
PyMT/iNOS
+/+ and PyMT/iNOS
–/– tumors. Data were
derived from examining 460 B6 PyMT/iNOS
+/+ and
260 PyMT/iNOS
–/– tumors
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123maintained PyMT/iNOS
–/– mice for up to
32 weeks and found no increase in metastatic
burden (data not shown), suggesting that the
decrease in metastasis is not due simply to the
delayed tumor latency in these mice.
Discussion
Mouse models of mammary tumorigenesis have
provided important insights into the molecular
basis of human breast cancer and are essential for
gathering preclinical data regarding therapeutic
drug efﬁcacy. The PyMT model in the FVB strain
has a mean tumor latency of 53 days and has been
used extensively in studies of mammary tumori-
genesis (Cardiff 2003; Muller and Neville 2001).
The model is frequently crossed with gene-
targeted strains that have been generated in the
B6/129 mixed background or backcrossed onto
the B6 background. We had highly variable
results examining iNOS effects in a mixed B6/
FVB PyMT background and sought to characterize
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Fig. 5 Tumor latency of individual B6 mammary glands.
Tumor latency was lower in the #1 mammary gland in
PyMT/iNOS
+/+ mice compared with all other mammary
glands (upper panel). A similar result was observed in
PyMT/iNOS
+/+ mice, with an increase in disparity between
the latency of the #1 gland and all other glands (middle
panel). When the #1 and #4 latencies for both genotypes
were overlayed, a greater difference in mean tumor
latency was observed between the #4 glands when
compared with the #1 glands (lower panel)
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Fig. 4 Distribution of B6 mammary gland tumor burden.
(A) Total tumor burden was signiﬁcantly lower in PyMT/
iNOS
–/– mice, ***P < 0.001. (B) Examination of individual
tumors indicated that a signiﬁcant difference in genotypes
was only found in the #3 and #4 mammary glands, although
in each gland the mean tumor burden was lower in PyMT/
iNOS
–/– mice. *P < 0.05 ANOVA followed by Bonferroni
post tests. PyMT/iNOS
+/+ B6 N = 24 (black bars), PyMT/
iNOS
–/– B6 N = 25 (grey bars)
Table 1 Quantitative analysis of tumor microvascular
density
Genotype Location N MVD (lm
2/mm
2)
PyMT/iNOS
+/+ #1 9 216 ± 20
PyMT/iNOS
+/+ #2–5 9 176 ± 12
PyMT/iNOS
–/– #1 6 201 ± 11
PyMT/iNOS
–/– #2–5 11 189 ± 11
Data are means ± SEM
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123the phenotype of this mutation in congenic FVB
and B6 strains. Our study demonstrates that the
genetic background of the PyMT model can affect
the ability to discern differences in phenotype due
to genetic alterations that require time to inﬂu-
ence tumor progression. Differences observed in
the B6 background were obscured in the FVB
background due to the signﬁcantly shorter tumor
latency and more rapid tumor growth in this
strain.
Further analysis of mammary tumorigenesis in
the B6 background indicated that tumor forma-
tion occurred in 2 phases: early, from 12–
17 weeks and late, from 19–23 weeks. It is the
early phase of tumor formation that is most
affected in the absence of iNOS, consistent with
recent data linking iNOS expression with tran-
scriptional upregulation of signal transducers and
activators of transcription 3 (STAT3) by nuclear
epidermal growth factor receptor (EGFR) (Lo
et al. 2005). EGFR/ErbB1, a member of the ErbB
family of receptor tyrosine kinases that signal via
the same pathways as PyMT (Webster et al.
1998), is also found in the nucleus of highly
proliferative cells where is functions as a tran-
scription factor (Marti et al. 1991; Wells and
Marti 2002). Structural and functional character-
ization of the iNOS promoter has identiﬁed
binding elements for both EGFR and STAT3
(Lo et al. 2005). Immunohistochemical studies of
breast carcinomas show that nuclear EGFR
positively correlates with iNOS and survival
analysis demonstrates that high levels of iNOS
are a prognostic indicator of poor survival (Lo
et al. 2005). Thus the B6 PyMT mice in the
presence or absence of iNOS deﬁciency are likely
to provide an important model for further anal-
ysis of these novel molecular interactions.
Mammary tumor latency for each of the ten
murine mammary glands has generally been
assumed to be stoichiometric. However our data
demonstrate that the #1 mammary glands have
tumor initiating properties that are distinct from
the other 4 pairs of mammary glands. The #1
mammary glands have the smallest fat pads and
are located in the head and neck region, which is
highly vascular, so we hypothesized that an
increase in vascular density in the #1 tumors
could be responsible for this difference. An
examination of the microvacular density (MVD)
of #1 tumors versus all others showed a trend in
which #1 tumors had a higher mean MVD than
#2–5 tumors as determined by quantitative anal-
ysis of CD31 staining. However, these values
were not statistically signiﬁcant, suggesting a
different mechanism is responsible for the ob-
served site-speciﬁc differences in tumor burden
and tumor latency. Other factors in the stromal
microevironment may also play a role in mediat-
ing this effect. The release of epidermal growth
factor (EGF) from the submandibular salivary
gland has been shown to promote mouse mam-
mary tumorigenesis in virus mediated and chem-
ical carcinogen induced models (Kurachi et al.
1985; Molinolo et al. 1998). The proximity of the
#1 glands to the submandibular gland make EGF
induced proliferation a plausible explanation,
however further investigations will be required
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Fig. 6 Tumor metastasis. (A) HE stained parafﬁn embed-
ded sections of PyMT/iNOS
+/+ (left panel) and PyMT/
iNOS
–/– (right panel) lungs. (B) Comparison of metastatic
tumor burden in FVB and B6 mice *P < 0.05 Mann-
Whitney U test. PyMT/iNOS
+/+ FVB N = 14, PyMT/
iNOS
–/– FVB N = 13, PyMT/iNOS
+/+ B6 N = 17, PyMT/
iNOS
–/– B6 N =2 1
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123to determine whether the release of this growth
factor primarily affects the #1 glands.
Another possible explanation for this intrigu-
ing difference is that the #1 mammary gland is
developmentally distinct from the other mam-
mary glands. The #1 gland is not the ﬁrst to
develop since placode 3 develops ﬁrst at E11.0–
11.5 on the ectodermal streak between the fore-
limb and hindlimb (Eblaghie et al. 2004; Mailleux
et al. 2002). Placodes 1 and 5 arise from the
axillary and inguinal streaks respectively and
placodes 4 and 2 form where the mammary line
abuts these streaks (Veltmaat et al. 2004). Recent
studies indicate that signaling molecules essential
for mammogenesis are placode dependent. Pla-
codes 2 and 3 do not form in the absence of Lef1
mediated canonical Wnt signaling (Boras-Granic
et al. 2006) and placodes 1, 2, 3 and 5 require
Fgf10 signaling from somites underlying the
ectoderm (Mailleux et al. 2002; Veltmaat et al.
2006). It is clear there are developmental differ-
ences between mammary glands and it is possible
that early developmental factors result in an
increased propensity for malignant transforma-
tion in the #1 mammary glands, though the
identity of these factors remains to be deter-
mined.
Since metastasis is an aspect of tumor progres-
sion that is critical to patient survival, we exam-
ined the effect of iNOS on tumor metastasis in
both the FVB and B6 backgrounds. No signiﬁcant
difference in metastatic burden was found in
PyMT/iNOS
–/– mice in the FVB background,
however the tumor burden was reduced in lungs
of PyMT/iNOS
–/– mice in the B6 background
compared with controls. Furthermore, the reduc-
tion in metastatic burden was not due simply to
the delayed tumor latency as we maintained
PyMT/iNOS
–/– mice longer to compensate for
the difference and found that this did not alter
our previous ﬁndings (Ellies et al. 2003).
Human clinical studies have associated in-
creased iNOS expression with poor prognosis in
breast cancer patients (Loibl et al. 2005), and the
use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) with a 22–39% reduction in the risk
of breast cancer (Harris et al. 2005; Khuder and
Mutgi 2001). To increase our understanding of
the molecular pathways involved in these effects,
it is essential to have animal models that recapit-
ulate the clinical ﬁndings. We have shown that in
the PyMT B6 background loss of iNOS, an
important inﬂammatory mediator, results in
increased tumor latency and decreased tumor
metastasis that is not due simply to the difference
in latency. This model will be useful in determin-
ing molecular pathways underlying the role of
iNOS in breast cancer.
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